HC Wainwright Reaffirms Buy Rating for Dianthus Therapeutics (NASDAQ:DNTH)

Dianthus Therapeutics (NASDAQ:DNTH)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a research report issued on Tuesday,Benzinga reports. They currently have a $40.00 target price on the stock. HC Wainwright’s target price would indicate a potential upside of 111.64% from the stock’s previous close.

Other analysts have also recently issued research reports about the stock. Wedbush reaffirmed an “outperform” rating and issued a $36.00 price objective on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Guggenheim reaffirmed a “buy” rating and issued a $84.00 price objective on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Seven analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $53.00.

Dianthus Therapeutics Stock Performance

Shares of NASDAQ:DNTH opened at $18.90 on Tuesday. The stock has a market capitalization of $607.18 million, a price-to-earnings ratio of -7.56 and a beta of 1.48. Dianthus Therapeutics has a 1-year low of $13.37 and a 1-year high of $32.27. The company’s fifty day moving average is $19.58 and its two-hundred day moving average is $22.27.

Dianthus Therapeutics (NASDAQ:DNTH) last released its quarterly earnings data on Monday, May 12th. The company reported ($0.82) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.86) by $0.04. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. The business had revenue of $1.16 million for the quarter, compared to analysts’ expectations of $0.81 million. Sell-side analysts expect that Dianthus Therapeutics will post -2.61 EPS for the current fiscal year.

Institutional Trading of Dianthus Therapeutics

Several institutional investors have recently made changes to their positions in DNTH. FMR LLC raised its position in Dianthus Therapeutics by 0.8% during the fourth quarter. FMR LLC now owns 4,439,281 shares of the company’s stock valued at $96,776,000 after acquiring an additional 36,133 shares in the last quarter. Octagon Capital Advisors LP raised its holdings in shares of Dianthus Therapeutics by 20.8% in the fourth quarter. Octagon Capital Advisors LP now owns 2,110,167 shares of the company’s stock valued at $46,002,000 after buying an additional 363,500 shares during the last quarter. TCG Crossover Management LLC bought a new position in shares of Dianthus Therapeutics in the fourth quarter valued at about $32,735,000. Braidwell LP raised its holdings in Dianthus Therapeutics by 144.4% during the 4th quarter. Braidwell LP now owns 1,206,589 shares of the company’s stock worth $26,304,000 after purchasing an additional 712,902 shares during the last quarter. Finally, Alliancebernstein L.P. raised its holdings in Dianthus Therapeutics by 13.4% during the 4th quarter. Alliancebernstein L.P. now owns 1,159,776 shares of the company’s stock worth $25,283,000 after purchasing an additional 136,633 shares during the last quarter. 47.53% of the stock is currently owned by institutional investors and hedge funds.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.